Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07527130

C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine & Health Section or approval by MAGPIES research group.
  • Be able to participate fully in all aspects of the study.
  • Have understood and signed study informed consent.

Exclusion criteria

  • Lacking the capacity to consent.
  • Prisoners and institutionalized individuals.
  • Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.

o Acceptable forms include:

  • Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
  • Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)
  • Intrauterine device (IUD)
  • Total hysterectomy or tubal ligation
  • Abstinence (no sex).
  • Those patients that have implants that would prevent them from having a PET Scan.
  • Patients that have claustrophobia.
  • Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

Treatment and study plan

C11 ER176 Tracer

Drug

C11 ER176 tracer will be administered by IV, followed by PET imaging of the brain to evaluate for neuroinflammation

Primary outcomes

  1. Degree of Neuroinflammation

    Time frame: Baseline reading only

    Estimation of areas degree of neuroinflammation determined by the radiologist

Study contacts

Contact information is provided by the study sponsor or research team.

Katie Cruz

CONTACT

[email protected]

507-284-5404

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Apr 14, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.